linjc16/ctgov huggingface dataset:
Uremic Toxins and Outcomes in Chronic Kidney Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this cohort study is: To investigate the etiology and epidemiology of comorbidities in CKD; To find out risk factors associated with the mortality of CKD; To find out uremic toxins which are related to the mortality and comorbidities of CKD; To focuse on the association between uremic toxins and inflammation, oxidative stress and nutritional status in CKD.

Detailed Description
-----------------
To investigate the etiology and epidemiology of comorbidities in CKD; To find out risk factors associated with the mortality of CKD; To find out uremic toxins which are related to the mortality and comorbidities of CKD; To focuse on the association between uremic toxins and inflammation, oxidative stress and nutritional status in CKD.

Official Title
-----------------
The Association Between Uremic Toxins and Outcomes and Comorbidities in Patients With CKD

Conditions
-----------------
Chronic Kidney Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥18 years old; clinically diagnosed with chronic kidney disease, according K/DOQI criteria. Exclusion Criteria: acute kidney injury history of kidney injury <3 months malignancy pregnancy incomplete clinical data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CKD-ND<br>patients with non-dialysis CKD | |
| CKD-MHD<br>patients with maintenance hemodialysis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comorbidities |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic kidney disease, uremic toxin, prognosis
Aqueous Urea Concentration May be Related to Cataract Development

Study Overview
=================
Brief Summary
-----------------
cataracts could be cured with eye drops. Some studies reported that in chronic renal failure, the occurrence of cataract is rare and the mechanism is unknown. The aim of this research is to describe correlation between urea concentration in the serum and aqueous humor and development of age related cataract.

Detailed Description
-----------------
The study was conducted in the departments of Ophthalmology and internal medicine, Asyut University hospitals, Egypt. Three groups of subjects were included: patients with age related cortical cataracts who are otherwise healthy (cases) and two control groups; first systemically healthy subjects with ocular problems other than cataract and a second control group of patients with impaired renal functions and are not on dialysis treatment and thus have elevated serum urea levels. Slit lamp examination was performed to evaluate crystalline lens for opacities. Measurement of serum urea was done for all study subjects. Aqueous humor urea concentration was done only for the group of patients who are planned to have intraocular surgery. For that purpose, 0.1 ml of aqueous humor will be aspirated at the start of routine intraocular surgery.

Official Title
-----------------
Aqueous Urea Concentration May be Related to Cataract Development

Conditions
-----------------
Cataract Cortical

Intervention / Treatment
-----------------
* Diagnostic Test: cortical cataract


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Senile Cortical cataract. Exclusion Criteria: Senile Nuclear cataract. Congenital cataract Traumatic cataract

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cortical cataract<br>patients with age related cortical cataracts who are otherwise healthy | Diagnostic Test: cortical cataract<br>* Blood urea<br>|
| ocular problems<br>systemically healthy subjects with ocular problems other than cataract | Diagnostic Test: cortical cataract<br>* Blood urea<br>|
| impaired renal functions<br>patients with impaired renal functions and are not on dialysis | Diagnostic Test: cortical cataract<br>* Blood urea<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood urea level | The relation between blood urea level and cataract | 1 Day |
New Technique in Congenital/Pediatric Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
In pediatric/congenital cataract surgery; multiple surgical interventions are performed, which needs multiple general anesthesias. Here, we describe a new technique, to end the operation in one session.

Detailed Description
-----------------
Generally, in congenital/pediatric cataract surgery, it might be possible to different multiple procedures with multiple general anesthesias. Here, the investigators found a new procedure to perform the cataract removal, intraocular implantation, and the anterior vitrectomy all in one session through a sclero-corneal tunnel. The corneoscleral tunnels are covered by the conjunctiva to abolish the need for both suturing and repeated general anesthesia to remove corneal sutures.

Official Title
-----------------
A Simplified Sclerocorneal Incision/Tunnel in Performing Congenital/Pediatric Cataract Surgery

Conditions
-----------------
Pediatric Cataract, Congenital Cataract

Intervention / Treatment
-----------------
* Other: The cataract surgery and the anterior vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Congenital/pediatric cataract Exclusion Criteria: Aphakic and pseudophakic
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: A simplified sclero-cornel tunnel/incision in performing the congenital/pediatric cataract surgery<br>Participitant | Other: The cataract surgery and the anterior vitrectomy<br>* Surgical<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Slit-lamp examination | To check the intra-ocular lens positioning | The fourth weeks postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Corneoscleral incision, Cataract surgery, Vitreorrhexis, Anterior vitrectomy
Urine Proteome of Patients Having Surgery

Study Overview
=================
Brief Summary
-----------------
The investigators are measuring novel proteins in the urine of patients having surgery.

Official Title
-----------------
Urine Proteome of Patients Undergoing Surgery

Conditions
-----------------
Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients > 18 years of age Undergoing surgery Exclusion Criteria: No formal exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients having surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in urine proteins after surgery. |  | Pre-op, intraoperative, post operatively (1-6 months) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients having surgery
CGH-array in Prenatal Diagnosis of Isolated Severe and Early Intra-uterine Growth Restriction

Study Overview
=================
Brief Summary
-----------------
According to french recommandations for IUGR management we have to propose a CGH-array analysis if the IUGR is severe (bellow the 3rd percentile) and early (in the second trimester). However there is no data to support this point of view.

Official Title
-----------------
CGH-array in Prenatal Diagnosis of Isolated Severe and Early Intra-uterine Growth Restriction

Conditions
-----------------
IUGR, Prenatal Disorder, Genetic Disease

Intervention / Treatment
-----------------
* Genetic: CGH array analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women fetus with an isolated intra-uterine growth restriction (IUGR) severe (bellow the third percentile on CFEF curves) and early (between 21 and 24 gestational weeks). Exclusion Criteria: associated IUGR (with other abnormalities during prenatal screening)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: CGH array analysis|CGH array analysis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of abnormal CGH-array in the groupe severe and early UGR |  | one-time (at the time of the analysis) |
The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway remodeling or scarring in subjects with COPD. Approximately 20 subjects with COPD will participate for approximately 7 weeks, with 10 receiving an active (BDP) inhaler with HFA-134a and 10 receiving a placebo.

Official Title
-----------------
The Effect of HFA-beclomethasone Dipropionate on Static Lung Volumes in COPD

Conditions
-----------------
COPD

Intervention / Treatment
-----------------
* Drug: HFA-134A Beclomethasone DIpropionate (QVAR)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD diagnosis FEV1/FVC<70% FEV1 50-80% predicted Albuterol response of <12% and <200mL or methacholine PC20 > 8mg/mL RV > 120% predicted DLCO < 80% smokers and nonsmokers Lower age limit 45 years Exclusion Criteria: Asthma Other chronic airway or parenchymal lung disease Other comorbid illness (including but not limited to DM, MI or CAD-related intervention in 6 months, neurologic disease, syncope) Use of any steroid (oral, IV, nasal, pulmonary) within 12 weeks Use of theophylline, leukotriene modifiers within 12 weeks Use of long-acting beta-agonists (formoterol, salmeterol) or anticholinergic (tiotropium)

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: HFA-134A Beclomethasone DIpropionate (QVAR)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spirometric response (FEV1) |  |  | 
| Lung volumes such as residual volume (RV), thoracic gas volume, total lung capacity (TLC) and the RV/TLC ratio |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis
Corpus Callosum Size in Patients With Pineal Cyst

Study Overview
=================
Brief Summary
-----------------
This study aims to determine size of corpus callosum on midsagittal MR scan in patients with a pineal cyst and to compare it with the control group without a pineal cyst.

Detailed Description
-----------------
A pineal cyst (PC) is a benign affection of the pineal gland, its prevalence in population reaches 1-2 %. Etiopathogenesis of PC is unknown, several hypotheses have been proposed. One of the hypothesis consider perinatal hypoxia as a causative factor for a development of PC in later life. Ozmen et al. showed significantly higher prevalence of PC in patients with cerebral palsy (p<0.001). Bregant et al. studied presence of PC in patients that suffered from a mild to moderate perinatal hypoxia. Prevalence of PC reached 36 % in these patients and presence of PC was associated with a atrophy of the corpus callosum (p<0.005). The atrophy of the corpus callosum is considered to be a sign of a periventricular leukomalacia, i.e. an ischemic insult in a perinatal period. In the present study, we are going to compare an area of corpus callosum on a midsagittal magnetic resonance T2-weighted scan in the group of patients with PC and in the control group without PC. The goal of the study is to determine if there is a relationship between atrophy of the corpus callosum and PC. Such finding would support abovementioned theory of etiopathogenesis of PC.

Official Title
-----------------
Corpus Callosum Size in Patients With Pineal Cyst

Conditions
-----------------
Pineal Gland Disorder, Corpus Callosum Atrophy, Cerebral Palsy

Intervention / Treatment
-----------------
* Diagnostic Test: MR of the brain


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3T MR examination of the brain including T2 sagittal scans Exclusion Criteria: other intracranial pathology discovered on the MR other known neurological disease (e.g. multiple sclerosis, stroke, tumor, etc.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group of patients with pineal cyst<br>Group of patients with pineal cyst | Diagnostic Test: MR of the brain<br>* MR of the brain without gadolinium, incl. T2-weighted image<br>|
| Control group<br>Group of subjects without pineal cyst | Diagnostic Test: MR of the brain<br>* MR of the brain without gadolinium, incl. T2-weighted image<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| size of corpus callosum | size of corpus callosum in mm2 measured on the midsagittal T2-weighted MR scan | time of the MR examination |
Fluoride Varnish for Treatment of White Spot Lesions

Study Overview
=================
Brief Summary
-----------------
Study will look at ability of fluoride varnish to remineralize white spot enamel lesions that can occur around the edge of fixed orthodontic brackets.

Detailed Description
-----------------
To determine the efficacy of 5% sodium fluoride varnish with tricalcium phosphate in reverting white spot lesions after fixed orthodontic treatment, compared with a fluoride gel.

Official Title
-----------------
Fluoride Varnish Application for Treatment of White Spot Lesion After Fixed Orthodontic Treatment. A Pilot Study.

Conditions
-----------------
White Spot Lesions

Intervention / Treatment
-----------------
* Device: Vanish Varnish
* Device: Pediagel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no systemic disease has completed fixed orthodontic treatment, brackets debonded has at least two teeth with whitre spot lesions has received conventional periodontal therapy after orthodontic tretament Exclusion Criteria: presence of enamel hypoplasia or dental fluorosis presence of tetracycline pigmentation periodontal pocketing of 3mm or greater taking antibiotics presence of carious cavities allergy to fluoride gel / varnish being used in study

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Pediagel<br>1.23% Acidulated Phosphate Fluoride Gel | Device: Pediagel<br>* 1.23% Acidulated Phosphate Fluoride Gel<br>|
| Experimental: 3M Vanish Varnish<br>5% sodium fluoride varnish | Device: Vanish Varnish<br>* 5% sodium fluoride varnish with tricalcium phosphate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DIAGNOdent Readings at Baseline, Three and Six Months - Intergroup Comparison | Outcome of fluoride varnish or gel application to white spot lesions as measured by DIAGNOdent device after orthodontic debonding. Values shown represent the mean DIAGNOdent reading. The DIAGNOdent scale spans values from 0 to 30+ where larger values indicate higher levels of demineralization. | Baseline, Three and Six Month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
white spot lesions, fixed orthodontic brackets, fluoride varnish, fluoride gel
Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

Study Overview
=================
Brief Summary
-----------------
This is a protocol for prescreening of participants who would like to be in clinical studies in our Center at Stanford.

Official Title
-----------------
Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

Conditions
-----------------
Food Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any individual with possible food allergy (as per their clinical history) who is interested in performing the gold standard food challenge for diagnosis. Exclusion Criteria: Any individual who does not consent Any individual who is currently taking oral steroids Any individual with moderate to severe asthma (FEV1<80%)

Ages Eligible for Study
-----------------
Minimum Age: 1 Week
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outcome of standardized food challenges | Standardized Oral food challenges will occur in a staged manner to diagnose food allergies | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin testing will occur to evaluate food allergen responses | Standardized skin testing will be performed to detect sensitivity to food allergens | 1 year |
Effect of Systemic Cooling in Vasospasms

Study Overview
=================
Brief Summary
-----------------
This study tests whether women with Vasospastic Syndrome (VS) react more intensive than controls with distal vasomotions and choroidal blood flow changes to internal cooling/warming and external cooling/warming.

Detailed Description
-----------------
Distal vasomotions and choroidal blood flow changes to internal cooling/warming and external cooling/warming was studied in VS and controls.Core cooling was induced by drinking of 250g ice/water mixture (4°C). Core warming was induced by drinking of 250g warm water (55°C). The study was controlled with respect to posture and room temperature.

Official Title
-----------------
Effect of Systemic Cooling in Vasospasms (Kühleffekte Beim Vasospastischen Syndrom)

Conditions
-----------------
Vasospastic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women luteal phase or contraceptives 19-35 years Exclusion Criteria: somatic diseases psychiatric diseases BMI > 25 BMI < 18

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LDF blood flow |  | repeated after each challenge | 
| LDF velocity |  | repeated after each challenge | 
| finger skin temperature |  | repeated after each challenge | 
| core body temperature |  | repeated after each challenge | 
| corneal temperature |  | repeated after each challenge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| subjective sleepiness |  | repeated after each challenge | 
| subjective ratings of thermal comfort |  | repeated after each challenge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vasospastic women, controls, core cooling, core warming, external cooling, external warming, LDF, choroidal blood flow, temperature, vasospastic subjects, normal subjects